NIH R01 · 2025
Systems biology to predict progression and treatment response in M avium complex pulmonary disease
PROJECT SUMMARY Prevalence of pulmonary disease due to non-tuberculous mycobacteria in the United States has doubled in the last 10 years, and Mycobacterium avium pulmonary disease (MAC-PD) is the most common. Treatment requires ≥3 antibiotics for >12 months and efficacy remain low. Given this intense treatment regimen and limited efficacy, antibiotic therapy is not always advisable. In fact, ~50% of patients will attain culture conversion with observation alone or with bronchial hygiene treatments. There is currently no way to predict which patients will improve with or without antibiotic treatment. The result of this uncertainty is prolonged ineffective treatment which risks side effects,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.